1. Home
  2. BOWN vs MDXH Comparison

BOWN vs MDXH Comparison

Compare BOWN & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BOWN
  • MDXH
  • Stock Information
  • Founded
  • BOWN 2023
  • MDXH 2003
  • Country
  • BOWN United States
  • MDXH Belgium
  • Employees
  • BOWN N/A
  • MDXH N/A
  • Industry
  • BOWN
  • MDXH
  • Sector
  • BOWN
  • MDXH
  • Exchange
  • BOWN Nasdaq
  • MDXH Nasdaq
  • Market Cap
  • BOWN 100.3M
  • MDXH 93.1M
  • IPO Year
  • BOWN 2023
  • MDXH 2021
  • Fundamental
  • Price
  • BOWN $10.92
  • MDXH $2.26
  • Analyst Decision
  • BOWN
  • MDXH Strong Buy
  • Analyst Count
  • BOWN 0
  • MDXH 2
  • Target Price
  • BOWN N/A
  • MDXH $7.00
  • AVG Volume (30 Days)
  • BOWN 40.2K
  • MDXH 137.5K
  • Earning Date
  • BOWN 01-01-0001
  • MDXH 11-06-2024
  • Dividend Yield
  • BOWN N/A
  • MDXH N/A
  • EPS Growth
  • BOWN N/A
  • MDXH N/A
  • EPS
  • BOWN 0.39
  • MDXH N/A
  • Revenue
  • BOWN N/A
  • MDXH $84,708,000.00
  • Revenue This Year
  • BOWN N/A
  • MDXH $27.57
  • Revenue Next Year
  • BOWN N/A
  • MDXH $20.09
  • P/E Ratio
  • BOWN $28.18
  • MDXH N/A
  • Revenue Growth
  • BOWN N/A
  • MDXH 33.01
  • 52 Week Low
  • BOWN $10.32
  • MDXH $1.55
  • 52 Week High
  • BOWN $10.98
  • MDXH $4.64
  • Technical
  • Relative Strength Index (RSI)
  • BOWN 53.13
  • MDXH 57.11
  • Support Level
  • BOWN $10.93
  • MDXH $2.12
  • Resistance Level
  • BOWN $10.97
  • MDXH $2.52
  • Average True Range (ATR)
  • BOWN 0.02
  • MDXH 0.16
  • MACD
  • BOWN -0.01
  • MDXH 0.01
  • Stochastic Oscillator
  • BOWN 14.29
  • MDXH 61.19

About BOWN Bowen Acquisition Corp

Bowen Acquisition Corp is a blank check company.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.

Share on Social Networks: